Wuhan Createrna Science and Technology Co., Ltd.

Building C2-2, Optical Valley Biological Town, No.666, Gaoxin Boulevard, Donghu New Tech D evelopment Zone, Wuhan, Hubei, China

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

42.9%

Phase 1

35.7%

Phase 3

21.4%

Trial Status Distribution

Completed

50.0%

Not yet recruiting

28.6%

Recruiting

21.4%

Clinical Trials

Trials sponsored by this organization (14)

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Not yet recruiting

interventional

Dec 202540 participants

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Phase 2

Not yet recruiting

interventional

Dec 202472 participants

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Phase 3

Not yet recruiting

interventional

Dec 2024810 participants

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Recruiting

interventional

Nov 2024120 participants

A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function

Phase 1

Completed

interventional

Sep 202424 participants

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Phase 3

Recruiting

interventional

Aug 202420 participants

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Phase 3

Recruiting

interventional

Aug 202466 participants

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

Phase 1

Not yet recruiting

interventional

Aug 202416 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations